{"disease":{"id":"t-cell-lymphoma-relapsed","name":"t cell lymphoma relapsed"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02348216","title":"Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":307,"lead_sponsor_name":"Kite, A Gilead Company","has_results":true},{"nct_id":"NCT04792489","title":"DALY II USA/ MB-CART2019.1 for DLBCL","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":248,"lead_sponsor_name":"Miltenyi Biomedicine GmbH","has_results":false},{"nct_id":"NCT03886831","title":"A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":232,"lead_sponsor_name":"Prelude Therapeutics","has_results":false},{"nct_id":"NCT05471843","title":"Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":125,"lead_sponsor_name":"BeiGene","has_results":false},{"nct_id":"NCT07502768","title":"Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":107,"lead_sponsor_name":"Rong Tao","has_results":false},{"nct_id":"NCT03932331","title":"Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":105,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT07523555","title":"Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":96,"lead_sponsor_name":"Beijing Biotech","has_results":false},{"nct_id":"NCT03206970","title":"Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":86,"lead_sponsor_name":"BeiGene","has_results":true},{"nct_id":"NCT03349333","title":"A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCL","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":85,"lead_sponsor_name":"Mundipharma (China) Pharmaceutical Co. Ltd","has_results":true},{"nct_id":"NCT05050630","title":"Phase II Trial of Tirelizumab Combined With R2-ICE Regimen in the Treatment of rrDLBCL/HGBL","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":73,"lead_sponsor_name":"Affiliated Hospital to Academy of Military Medical Sciences","has_results":false},{"nct_id":"NCT03496779","title":"Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":71,"lead_sponsor_name":"The Lymphoma Academic Research Organisation","has_results":false},{"nct_id":"NCT06966154","title":"A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":68,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT05805605","title":"Allo HSCT Using RIC and PTCy for Hematological Diseases","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":56,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":false},{"nct_id":"NCT05140382","title":"AZD4573 as Monotherapy or in Combinations With Anti-cancer Agents in Patients With r/r PTCL or r/r cHL","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":52,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT03939026","title":"Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"Allogene Therapeutics","has_results":false},{"nct_id":"NCT07535710","title":"Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":37,"lead_sponsor_name":"Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT04763616","title":"Study of Isatuximab and Cemiplimab in Relapsed or Refractory Natural Killer/T-cell Lymphoid Malignancy","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":37,"lead_sponsor_name":"Won Seog Kim","has_results":false},{"nct_id":"NCT03046953","title":"Avelumab in Relapsed and Refractory Peripheral T-cell Lymphoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":35,"lead_sponsor_name":"University of Birmingham","has_results":true},{"nct_id":"NCT04191187","title":"Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"H. Lee Moffitt Cancer Center and Research Institute","has_results":true},{"nct_id":"NCT06151106","title":"Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":33,"lead_sponsor_name":"The First Affiliated Hospital of Xiamen University","has_results":false},{"nct_id":"NCT06158386","title":"Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":33,"lead_sponsor_name":"The First Affiliated Hospital of Xiamen University","has_results":false},{"nct_id":"NCT07234045","title":"A Clinical Study to Explore CT1195E in Patients With Relapsed/Refractory B-Cell Neoplasms","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":30,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT06789159","title":"A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Thomas Jefferson University","has_results":false},{"nct_id":"NCT02341014","title":"Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":27,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":true},{"nct_id":"NCT04447027","title":"Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06696846","title":"CD70-CAR-NK Cell Therapy for T Cell Lymphoma and Acute Myeloid Leukemia","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":25,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT03674411","title":"Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":22,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":true},{"nct_id":"NCT03552692","title":"Use of Venetoclax as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell Lymphoma","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":22,"lead_sponsor_name":"Fondazione Italiana Linfomi - ETS","has_results":false},{"nct_id":"NCT06508463","title":"Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":21,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT05360238","title":"Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":20,"lead_sponsor_name":"Mustang Bio","has_results":false},{"nct_id":"NCT03994913","title":"Clinical Trial to Evaluate CD19 CAR T (CT032) in Patients With Relapsed and/or Refractory Non-Hodgkin's B Cell Lymphoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"CARsgen Therapeutics Co., Ltd.","has_results":false},{"nct_id":"NCT05963217","title":"Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":19,"lead_sponsor_name":"University Health Network, Toronto","has_results":false},{"nct_id":"NCT02722668","title":"UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":true},{"nct_id":"NCT07478848","title":"Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":14,"lead_sponsor_name":"Abramson Cancer Center at Penn Medicine","has_results":false},{"nct_id":"NCT03774654","title":"CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":13,"lead_sponsor_name":"Baylor College of Medicine","has_results":false},{"nct_id":"NCT02689453","title":"Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":11,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06732492","title":"RD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":10,"lead_sponsor_name":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","has_results":false},{"nct_id":"NCT05054257","title":"CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":10,"lead_sponsor_name":"Institute of Hematology and Blood Transfusion, Czech Republic","has_results":false},{"nct_id":"NCT03488251","title":"PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":8,"lead_sponsor_name":"Molecular Templates, Inc.","has_results":true},{"nct_id":"NCT04251065","title":"Daratumumab Plus Gemcitabine, Dexamethasone, Cisplatin in pt R/R CD38+ PTCL-NOS, AITL and TFH","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":8,"lead_sponsor_name":"Fondazione Italiana Linfomi - ETS","has_results":true},{"nct_id":"NCT05645744","title":"Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.","phase":"","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"Mustang Bio","has_results":false},{"nct_id":"NCT03153462","title":"Axicabtagene Ciloleucel Expanded Access Study","phase":"","overall_status":"APPROVED_FOR_MARKETING","enrollment_count":null,"lead_sponsor_name":"Kite, A Gilead Company","has_results":false}],"total":42},"guidelines":[],"source":"Drug Landscape verified database"}